SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

SAB Biotherapeutics, Inc.NASDAQ: SABS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$21.63M, compared with -$9.23M a year earlier. Trailing-twelve-month EBITDA was -$9.46M.

Context

  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$62.73M (-478.0%) for the fiscal year ending Dec 2026, a slowdown from the +157.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$21.63M-19.8% QoQ
Last fiscal yearDec 2025
$16.6M+157.2% YoY
LTMJun 2026
-$9.46M+71.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-134.4%-153.6%-19.2 pp
1 year+157.2%-478.0%-635.2 pp
3-year CAGR———
5-year CAGR+4.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
16.6M USD
Year-over-year change
+157.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SABS compares with its peers on the latest reported figures

  • SABS's LTM Jun 2026 EBITDA of -$9.46M is the 2nd highest of the 5 companies compared; the peer median is -$23.6M.
  • Its year-over-year change of +71.7% is the 3rd highest of 5, against a peer median of +47.3%.
SABS Competitors Peer median
EBITDA for SABS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M +154.8%—41.2%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$9.46M +71.7%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-$11.36M +79.6%—30.6%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$35.85M -213.1%——
BOLDBoundless Bio, Inc.LTM Mar 2026-$54.78M +15.1%——
Peer median (excluding SABS) -$23.6M+47.3%—35.9%

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.88M23.9M2.24M1.32M0
Cost of Revenue1.65M3.29M3.75M4.79M3.08M
Gross Profit59.22M20.61M(1.51M)(3.47M)(3.08M)
Gross Margin97.3%86.2%-67.3%-262.4%—
Research & Development57.18M36.44M16.52M30.16M34.35M
Selling, General & Admin17.09M16.38M23.8M9.28M14.6M
Operating Expenses72.62M49.53M36.57M39.44M45.87M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
EBITDA(15.2M)(15.12M)(38.13M)(28.99M)16.6M
EBITDA Margin-25.0%-63.3%-1703.1%-2192.5%—
Operating Income(13.39M)(28.92M)(38.08M)(42.91M)(48.95M)
Operating Margin-22.0%-121.0%-1700.5%-3244.9%—
Interest Income23.12K71.07K584.97K1.29M1.43M
Interest Expense294.46K301.58K315.28K318.4K240.66K
Other Income / Expenses(3.75M)10.2M(4.12M)8.81M62.23M
Income Before Tax(17.15M)(18.72M)(42.19M)(34.11M)13.27M
Pre-Tax Margin-28.2%-78.3%-1884.5%-2579.0%—
Income Tax Expense025.63K000
Net Income(17.15M)(18.74M)(42.19M)(34.11M)13.27M
Net Margin-28.2%-78.4%-1884.5%-2579.0%—
EPS (Basic)(3.94)(4.31)(7.64)(3.68)0.22
EPS (Diluted)(6.30)(4.31)(7.64)(3.68)(0.79)
Weighted Avg Shares4.35M4.35M5.52M9.26M19.31M
Weighted Avg Shares (Diluted)2.73M4.35M5.52M9.26M61.34M

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.